AU2019234576B2 - Methods and compositions for use of tumor self-antigens in adoptive immunotherapy - Google Patents

Methods and compositions for use of tumor self-antigens in adoptive immunotherapy

Info

Publication number
AU2019234576B2
AU2019234576B2 AU2019234576A AU2019234576A AU2019234576B2 AU 2019234576 B2 AU2019234576 B2 AU 2019234576B2 AU 2019234576 A AU2019234576 A AU 2019234576A AU 2019234576 A AU2019234576 A AU 2019234576A AU 2019234576 B2 AU2019234576 B2 AU 2019234576B2
Authority
AU
Australia
Prior art keywords
cancer
cell
cells
antigen
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019234576A
Other languages
English (en)
Other versions
AU2019234576A1 (en
Inventor
John M. Maris
Mark YARMARKOVICH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Childrens Hospital of Philadelphia CHOP
Original Assignee
Childrens Hospital of Philadelphia CHOP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Hospital of Philadelphia CHOP filed Critical Childrens Hospital of Philadelphia CHOP
Publication of AU2019234576A1 publication Critical patent/AU2019234576A1/en
Application granted granted Critical
Publication of AU2019234576B2 publication Critical patent/AU2019234576B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Developmental Biology & Embryology (AREA)
AU2019234576A 2018-03-12 2019-03-12 Methods and compositions for use of tumor self-antigens in adoptive immunotherapy Active AU2019234576B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862641541P 2018-03-12 2018-03-12
US62/641,541 2018-03-12
PCT/US2019/021827 WO2019178081A1 (en) 2018-03-12 2019-03-12 Methods and compositions for use of tumor self-antigens in adoptive immunotherapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2026203058 Division 2019-03-12

Publications (2)

Publication Number Publication Date
AU2019234576A1 AU2019234576A1 (en) 2020-10-08
AU2019234576B2 true AU2019234576B2 (en) 2026-02-05

Family

ID=67908079

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019234576A Active AU2019234576B2 (en) 2018-03-12 2019-03-12 Methods and compositions for use of tumor self-antigens in adoptive immunotherapy

Country Status (6)

Country Link
US (1) US12357694B2 (https=)
EP (2) EP4197552A1 (https=)
JP (2) JP2021517810A (https=)
AU (1) AU2019234576B2 (https=)
CA (1) CA3101310A1 (https=)
WO (1) WO2019178081A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013059740A1 (en) 2011-10-21 2013-04-25 Foundation Medicine, Inc. Novel alk and ntrk1 fusion molecules and uses thereof
US11230589B2 (en) 2012-11-05 2022-01-25 Foundation Medicine, Inc. Fusion molecules and uses thereof
US11965892B2 (en) 2017-02-12 2024-04-23 Biontech Us Inc. HLA-based methods and compositions and uses thereof
KR20240091046A (ko) * 2018-12-21 2024-06-21 바이오엔테크 유에스 인크. Hla 클래스 ii-특이적 에피토프 예측 및 cd4+ t 세포 특징화를 위한 방법 및 시스템
EP4359570A4 (en) 2021-06-25 2025-04-30 Foundation Medicine, Inc. METHODS OF USING SOMATIC HLA-I LOH TO PREDICT RESPONSE IN IMMUNE CHECKPOINT INHIBITOR-TREATED PATIENTS WITH LUNG CANCER
CN115636874A (zh) * 2021-07-19 2023-01-24 武汉市朗典精医生物科技有限公司 制备神经肽y（npy）抗体及建立检测npy方法
US20240352130A1 (en) * 2021-08-24 2024-10-24 The Children's Hospital Of Philadelphia Peptide-centric chimeric antigen receptors to cancer self-peptides
EP4399710A2 (en) * 2021-09-10 2024-07-17 Immunoscape Pte. Ltd. Systems and methods for the identification of target-specific t cells and their receptor sequences using machine learning
WO2023235882A2 (en) * 2022-06-03 2023-12-07 Fred Hutchinson Cancer Center Immunotherapy targeting egfr antigens
WO2024178354A2 (en) * 2023-02-24 2024-08-29 The Children's Hospital Of Philadelphia Improved phox2b pc-car generation based on structure and saturation mutagenesis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030224424A1 (en) * 2002-04-08 2003-12-04 Garcia-Barcelo Maria Mercedes PHOX2B polymorphisms as hirschsprung's disease diagnostic markers and methods based thereon

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7109030B2 (en) 2000-03-31 2006-09-19 Nuvelo, Inc. Methods of therapy and diagnosis using insulin-like growth factor binding protein-like polypeptides and polynucleotides
US7919467B2 (en) * 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
WO2004007770A2 (en) 2002-07-10 2004-01-22 Oncotherapy Science, Inc. Method for diagnosis of intestinal-type gastric tumors
EP1549676A1 (en) 2002-09-30 2005-07-06 Oncotherapy Science, Inc. Genes and polypeptides relating to human myeloid leukemia
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
CN104066746B (zh) * 2011-10-28 2017-12-05 肿瘤疗法科学股份有限公司 Topk肽及包含它们的疫苗
GB201501017D0 (en) * 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
US10335471B2 (en) 2015-08-28 2019-07-02 Immatics Biotechnologies Gmbh Method for treating cancer with activated T cells
AU2017254477A1 (en) * 2016-04-18 2018-11-01 Jennifer G. ABELIN Improved HLA epitope prediction
GB201609193D0 (en) * 2016-05-25 2016-07-06 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers
US20180028634A1 (en) 2016-07-29 2018-02-01 Lan Bo Chen Method for prolonging and enhancing anti-tumor vaccine response

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030224424A1 (en) * 2002-04-08 2003-12-04 Garcia-Barcelo Maria Mercedes PHOX2B polymorphisms as hirschsprung's disease diagnostic markers and methods based thereon

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Phox2b (B-11): sc-376997", SANTA CRUZ BIOTECHNOLOGY, INC., pages 1 - 1, XP093041766, Retrieved from the Internet <URL:https://datasheets.scbt.com/sc-376997.pdf> [retrieved on 20230424] *
LIQUN YANG ET AL: "PHOX2B Is Associated with Neuroblastoma Cell Differentiation", CANCER BIOTHERAPY & RADIOPHARMACEUTICALS, vol. 31, no. 2, 1 March 2016 (2016-03-01), US, pages 44 - 51 *
REGADAS ISABEL ET AL: "Several Cis-regulatory Elements Control mRNA Stability, Translation Efficiency, and Expression Pattern of Prrxl1 (Paired Related Homeobox Protein-like 1)", Jnl. OF BIOL. CHEM., v. 288, no. 51, 2013-12-20, p36285-36301 *

Also Published As

Publication number Publication date
JP2021517810A (ja) 2021-07-29
US12357694B2 (en) 2025-07-15
WO2019178081A1 (en) 2019-09-19
EP4197552A1 (en) 2023-06-21
JP2024009860A (ja) 2024-01-23
AU2019234576A1 (en) 2020-10-08
EP3765071A4 (en) 2022-05-25
CA3101310A1 (en) 2019-09-19
JP7853938B2 (ja) 2026-04-30
US20210213058A1 (en) 2021-07-15
EP3765071A1 (en) 2021-01-20

Similar Documents

Publication Publication Date Title
AU2019234576B2 (en) Methods and compositions for use of tumor self-antigens in adoptive immunotherapy
Wisdom et al. Single cell analysis reveals distinct immune landscapes in transplant and primary sarcomas that determine response or resistance to immunotherapy
TWI832035B (zh) 結合ccr8之抗體及融合蛋白及其用途
JP2020530277A (ja) 反復投与のための細胞免疫療法
EP3362074A2 (en) Regulatory t cell pd-1 modulation for regulating t cell effector immune responses
JP2019512271A (ja) Ｔ細胞疲弊状態特異的遺伝子発現調節因子およびその使用
CN111148518A (zh) 使用cdk4/6抑制剂调控调节性t细胞和免疫应答的方法
WO2020072126A2 (en) Modulating ptpn2 to increase immune responses and perturbing gene expression in hematopoietic stem cell lineages
CN114929853A (zh) 用于治疗胶质母细胞瘤和其他癌症的天然杀伤细胞免疫疗法
US20220378890A1 (en) Immunogenic egfr peptide compositions and their use in the treatment of cancer
WO2019183610A1 (en) Tissue resident memory cell profiles, and uses thereof
TW202325722A (zh) 識別ｈｐｖ１６ ｅ７抗原之結合蛋白及其用途
EP3397961A1 (en) Methods for identifying and treating hemoglobinopathies
JP2025515324A (ja) がんを処置するためのキメラ抗原受容体改変調節性ｔ細胞
US20210401887A1 (en) T cells from lymphatic fluid for diagnostic and therapeutic use
US20240417802A1 (en) Immunotherapeutic methods for treating cancer
JP2022513082A (ja) 免疫応答を調節するためのＩＲＥ１α－ＸＢＰ１シグナル伝達経路バイオマーカーの使用
US12552851B2 (en) T cell receptors with VGLL1 specificity and uses thereof
US20250213614A1 (en) Modified RELA Protein for Inducing Interferon Expression and Engineered Immune Cells with Improved Interferon Expression
US20260048106A1 (en) Immunotherapy targeting tumor transposable element derivedneoantigenic peptides in glioblastoma
WO2025122813A1 (en) Protecting cell therapies from tgf-beta induced immunosuppression
Kerr Modulation of T Cells to Promote an Anti-Tumor Response: Activation And Inhibition Of T Cells For Efficacy In T-Cell Lymphomas And Melanoma
WO2025122500A1 (en) Esr1 gene fusions and uses thereof
TW202430545A (zh) Ｍａｇｅａ１免疫原性肽、識別ｍａｇｅａ１免疫原性肽之結合蛋白及其用途
CN117794944A (zh) 靶向肿瘤抗原的方法和材料